Inhibrx Cuts R&D Costs Sharply as Two Clinical Trials Push Toward Key 2026 Milestones
Streamlined Operations Reveal Substantial Expense Declines
Inhibrx Biosciences, Inc. (NASDAQ: INBX) reported its Fourth Quarter and Fiscal Year 2025 financial results, highlighting sharp year-over-year reductions in both research and development (R&D) and general and administrative (G&A) expenses. These efficiency gains come as the company pivots to focus on two core clinical programs after selling its INBRX-101 asset to Sanofi in mid-2024.
Expense Cuts Dominate the Financial Picture
R&D expenses fell to $113.03 million for full-year 2025, down from $203.74 million in 2024—a reduction of nearly 45%. The latest quarter alone saw costs fall to $25.35 million, reflecting lower spending on major trials as enrollment winds down.
G&A costs also came down significantly, totaling $23.30 million in 2025 compared to $127.91 million in 2024. Management credited the drop to the absence of one-time legal and advisory fees tied to last year’s asset sale, and a resolution of legal proceedings.
| Metric | Q4 2025 | Q4 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| R&D Expense ($M) | 25.35 | 33.37 | 113.03 | 203.74 |
| G&A Expense ($M) | 5.57 | 16.66 | 23.30 | 127.91 |
| Net Income (Loss) ($M) | -32.83 | -47.87 | -140.06 | 1,687.57 |
Cash Position Remains Solid Despite Quarterly Loss
At year-end 2025, Inhibrx reported $124.22 million in cash and equivalents. After securing $75 million via an amended loan agreement with Oxford Finance in March 2026, liquidity remains strong to fund near-term development and regulatory activities.
Balance Sheet: Leverage Increases, Equity Drops
| Metric | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash & Equivalents ($M) | 124.22 | 152.60 |
| Total Assets ($M) | 146.48 | 180.77 |
| Long-term Debt ($M) | 100.56 | 0.00 |
| Stockholders' Equity ($M) | 7.99 | 133.58 |
Increased leverage (long-term debt up to $100.56 million) and a drop in stockholders’ equity (now just $7.99 million) reflect post-transaction restructuring and a year of operating losses.
2026 Clinical and Regulatory Milestones Take Center Stage
With the portfolio streamlined, upcoming value drivers are clear:
- Biologics License Application (BLA) for ozekibart (INBRX-109) is on track for early Q2 2026—for the treatment of unresectable/metastatic conventional chondrosarcoma.
- Phase 1/2 colorectal cancer cohort data for ozekibart and meetings with the FDA over accelerated approval for Ewing sarcoma and fourth-line colorectal cancer are expected later in 2026.
- INBRX-106 will report interim head and neck cancer trial data in Q2 2026 and progression-free survival results at the ESMO Congress by year-end.
Bottom Line: Structurally Lean, Outcome-Focused
Inhibrx enters 2026 with material improvements in cost structure, a stable cash foundation, and a clinical pipeline aligned for late-stage milestones and regulatory engagement. While operational losses remain, the significant expense reset and targeted R&D investments put the spotlight squarely on upcoming trial readouts and FDA submissions.
Investors following INBX should watch closely as the company approaches a pivotal year where multiple late-stage data readouts and regulatory catalysts could reset the outlook—and the risk profile—for this small-cap biotech.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI